COPENHAGEN (Reuters) -Wegovy-maker Novo Nordisk lowered its full-year profit and sales forecasts again on Wednesday, in an ...

Wegovy-maker Novo Nordisk lowered its full-year profit and sales forecast on Wednesday in an early blow to the Danish ...

Novo Nordisk CEO Maziar Mike Doustdar discusses demand for the Danish firm's weight-loss drug Wegovy and diabetes medication ...

Denmark's Novo Nordisk, the maker of Ozempic and Wegovy obesity drugs, said on Wednesday it was lowering its 2025 outlook for the third time this year, after posting tepid third-quarter results.

Novo Nordisk (NVO) said Wednesday it has agreed to the U.S. Inflation Reduction Act’s (IRA) negotiated maximum fair prices ...

The firm says it now expects full-year operating profit to grow between 4% and 7% in 2025 Read more at The Business Times.

Novo Nordisk said the overhaul resulted in one-off costs of about DKK 9 billion in 2025, including DKK 5 billion in severance ...

Henrik Wulff, EVP of Manufacturing at Novo Nordisk, is stepping down after serving since 2015. The announcement came during the company's Q3 earnings report.

Dow Jones Top Company Headlines at 5 AM ET: Ozempic Maker Novo Nordisk Lowers Growth Outlook of Its Blockbuster Drugs | XPeng ... Ozempic Maker Novo Nordisk Lowers Growth Outlook of Its Blockbuster ...

LONDON () -Wegovy maker Novo Nordisk said on Wednesday that its executive vice president in charge of manufacturing was ...

European shares hit a two-week low on Wednesday, weighed by a selloff in technology stocks that have been at the centre of ...